BOTULAX®

What Is BOTULAX® — And Why Does Brand Comparison Matter?

BOTULAX® is produced by Hugel Inc., a South Korean medical aesthetics manufacturer, and is used in South Korea and other CE-marked markets [3]. As a highly purified clostridium botulinum toxin type A formulation, it is lyophilized (freeze-dried) for stability during storage and transport [4].

A few structural facts worth holding onto before comparing brands:

• BOTULAX® is supplied in four vial sizes: 50U, 100U, 200U, and 300U.
• CE marking is a product-specific conformity designation used in applicable European markets, and it is not equivalent to FDA approval.
• Manufacturing takes place under South Korean quality control standards, with the same underlying purification process Hugel applies across its BTX-A portfolio.

A practitioner who treats “Botox” as a generic shorthand for all purified botulinum toxin brands risks conflating products that behave differently in practice. The same applies when practitioners buy Korean botox products as a group, since BOTULAX®, NABOTA®, and LIZTOX® differ in INN, regulatory footprint, and handling. Before any decision to order BOTULAX® wholesale or source it through a distributor, understanding where it sits relative to Western and other Korean brands is the more useful starting point than price alone.

BOTULAX® vs BOTOX® — The Brand vs Active Substance Distinction

Clinically, BOTULAX® and BOTOX® are not the same product.

• BOTULAX® contains letibotulinumtoxinA.
• BOTOX® (AbbVie) contains onabotulinumtoxinA.
• BOTULAX® and BOTOX® are distinct products with different nonproprietary naming and labeling, so they should not be treated as interchangeable.

Several botulinum toxin type A products are used globally, each with its own labeling and regulatory profile. A “unit” of one brand’s toxin does not necessarily equal a unit of another’s in clinical effect, so protocols developed for one product should not be assumed to transfer directly to another without adjustment. Practitioners who buy botulinum toxins based on brand familiarity alone may overlook meaningful differences in formulation, regulatory status, and unit equivalence across the category.

Regulatory Status — CE Marking, FDA, and South Korean Approval

Regulatory status is where BOTULAX® and its Hugel stablemate LETYBO® most often get confused, so it’s worth separating clearly.

• BOTULAX® is described as CE-marked in applicable European markets and holds MFDS approval in South Korea, its home market [3].
• BOTULAX® does not hold FDA approval for the United States.
• LETYBO® (letibotulinumtoxinA-wlbg) is a separate Hugel formulation with a distinct INN, and it received FDA approval on February 29, 2024, for the temporary improvement of moderate to severe glabellar lines [2].

As a prescription-only pharmaceutical, BOTULAX® is restricted to licensed medical practitioners in every market where it is available; it is not a product for self-administration or unsupervised use under any circumstances.

The practical takeaway for a US-based practitioner: if the goal is an FDA-approved Hugel product, that product is LETYBO®, not BOTULAX®. Treating the two as interchangeable because they share a manufacturer would be a regulatory error, not just a labeling one.

BOTULAX® Vial Sizes — Product Range and Clinical Matching

BOTULAX® is available across four vial sizes, and the comprehensive product details and usage for each are laid out in the product’s instructions for use (IFU), which should be the primary reference for dosing rather than general comparison content like this.

• 50U: Suited to precision work and fine-line correction where smaller total dose is appropriate.
• 100U: The standard aesthetic vial and the most commonly ordered size in day-to-day practice. BOTULAX® 100 units accounts for the majority of aesthetic orders across CE-marked markets.
• 200U: Used where higher total volume is needed across broader treatment areas.
• 300U: Typically reserved for hyperhidrosis, larger treatment areas, or therapeutic indications requiring a higher unit count per session. The BOTULAX® 300U comprehensive product details are contained in the vial-specific IFU.

Vial selection should follow the treatment plan and patient assessment, not the other way around; the existence of a 300U option doesn’t imply every patient needs it.

Reconstitution, Dosage, and Administration

BOTULAX® 100 reconstitution follows a standard dilution approach, though exact protocols should always defer to the current IFU rather than general guidance:

• Add 2.5 to 5 mL of sterile 0.9% saline to the 100U vial, rotating gently rather than shaking to avoid denaturing the protein.
• A 2.5 mL dilution yields roughly 4U per 0.1 mL; a 5 mL dilution yields roughly 2U per 0.1 mL.
• Reconstituted product should be used within 24 hours and kept refrigerated in the interim.

The IFU allows up to 24 hours post-reconstitution, but many practitioners prefer to administer within 4 hours where possible, since potency is generally considered most reliable closer to the point of mixing.

BOTULAX® post-treatment precautions that are typically communicated to patients include:

• Avoiding rubbing or massaging the treated area.
• Avoiding strenuous exercise for approximately 24 hours.
• Remaining upright for around 4 hours post-injection.
• Avoiding alcohol and excessive heat exposure (saunas, hot showers) in the immediate aftermath.

Treatment Areas and Indications

BOTULAX® is used across a fairly broad range of aesthetic and therapeutic indications, subject to market-specific approval status:

• Upper face: Glabellar lines, forehead lines, crow’s feet. These are among the most common wrinkle reduction injections performed in aesthetic practice [4].
• Lower face and neck: Masseter reduction, lip flip, chin dimpling (peau d’orange), platysmal bands.
• Body: Hyperhidrosis, generally using the 200U or 300U vials given the larger treatment surface.
• Therapeutic: Cervical dystonia, blepharospasm, and spasticity in some markets [1], though practitioners should confirm indication-specific approval locally before treating outside standard aesthetic use.

How BOTULAX® Compares to Other BTX-A Brands

BOTULAX® vs XEOMIN®

The most significant structural difference between these two is in formulation philosophy. XEOMIN® (incobotulinumtoxinA, Merz) is a “naked” toxin with no complexing proteins, which theoretically reduces long-term immunogenicity risk. BOTULAX® contains letibotulinumtoxinA with standard complexing proteins. XEOMIN® can also be stored at room temperature (up to 25°C) before reconstitution, whereas BOTULAX® requires refrigerated storage at 2°C to 8°C throughout its shelf life [3].

XEOMIN® is both FDA-approved and CE-marked for multiple indications; BOTULAX® is MFDS-approved in South Korea and CE-marked in applicable markets [3]. XEOMIN® is typically priced at a premium relative to Korean BTX-A products. Pricing, regional availability, and clinical needs also influence product selection.

BOTULAX® vs LETYBO®

BOTULAX® and LETYBO® represent distinct regional brand designations from Hugel targeting different regulatory markets and should not be treated as interchangeable in practice. LETYBO® carries the specific FDA-assigned designation letibotulinumtoxinA-wlbg for the US market, whereas BOTULAX® is distributed internationally under Hugel’s domestic line.

In CE-marked markets, LETYBO® may be available alongside BOTULAX®, depending on local regulations. Practitioners typically compare approved indications, regulatory status, product labeling, and institutional purchasing policies.

BOTULAX® vs INNOTOX®

INNOTOX® (Medytox) is the only commercially available liquid (pre-diluted) BTX-A, eliminating the reconstitution step entirely. BOTULAX® is a lyophilized powder that must be mixed with sterile saline before administration. BOTULAX® is CE-marked in applicable European markets; INNOTOX® does not currently hold CE marking or FDA approval for aesthetic use [3]. INNOTOX®’s liquid formulation also makes it particularly sensitive to freezing during storage and transit. When comparing INNOTOX® with BOTULAX®, practitioners often consider formulation, storage requirements, preparation convenience, and regional regulatory status.

BOTULAX® vs NABOTA®

Both originate in South Korea, but they contain different active ingredients (BOTULAX® contains letibotulinumtoxinA, while NABOTA® contains prabotulinumtoxinA), come from different manufacturers, and carry different regulatory profiles. NABOTA® is FDA-approved in the United States under the brand name Jeuveau® (Evolus, approved 2019), while BOTULAX® has not received FDA approval [3]. In CE-marked markets, NABOTA® and BOTULAX® may both be available, depending on local regulations. Although their dosing is broadly comparable in clinical practice, they should not be substituted without following each product’s prescribing information. Practitioners also evaluate supplier reliability, pricing, and regional regulatory requirements when selecting between the two.

BOTULAX® vs LIZTOX®

BOTULAX® and LIZTOX® are both lyophilized Korean botulinum toxin type A products that require reconstitution with sterile saline before injection. Manufactured by Huons, LIZTOX® has expanded into several European markets as a cost-competitive option. No published head-to-head randomized controlled trial directly compares their clinical performance, so comparative claims should rely on each product’s individual clinical evidence [3]. Practitioners typically compare the two based on regional regulatory approval, pricing, supplier qualifications, cold-chain compliance, and local product availability.

Onset, Duration, and Clinical Performance

Like other botulinum toxin type A products, BOTULAX® works by temporarily blocking the release of acetylcholine at the neuromuscular junction, reducing muscle activity over time rather than immediately after injection [4]. Most patients notice the first effects within 3 to 7 days, while full results typically develop after 10 to 14 days [4]. Individual response can vary depending on factors such as the treatment area, muscle strength, dose administered, and injection technique.

In aesthetic applications, results generally last 3 to 4 months, although some patients may continue to see visible improvement for up to 6 months before muscle activity gradually returns [4]. Clinical studies suggest that BOTULAX® provides efficacy and duration comparable to other botulinum toxin type A products used for aesthetic indications, although direct head-to-head randomized comparisons with BOTOX® remain limited [1][5].

When reviewing BOTULAX® before and after results, it is important to remember that treatment outcomes depend not only on the product itself but also on injection technique, treatment planning, patient characteristics, and the injector’s clinical expertise.

Storage and Cold-Chain Requirements

Storage discipline matters more with botulinum toxin products than with many other pharmaceuticals, given the protein’s sensitivity to temperature and light.

• Unopened vials require storage at 2°C to 8°C.
• Freezing should be avoided at all stages.
• Vials should be protected from light throughout storage and transit.
• Reconstituted product has a 24-hour maximum use window under refrigeration.

Because of these requirements, cold-chain transit is non-negotiable for BOTULAX® shipping. Practitioners who order BOTULAX® online should inspect packaging on arrival, confirm that temperature indicators (where used) show the product remained within the recommended range, and verify expiry dates before use. Any product arriving with signs of a broken cold chain should not be used, regardless of how minor the deviation appears.

BOTULAX® Price

The BOTULAX® price varies based on several factors rather than a fixed cost. Common considerations include:

• Vial strength (50U, 100U, 200U, or 300U)
• Regional market
• Purchase volume
• Distribution channel
• Shipping requirements
• Currency fluctuations

While Korean BTX-A products are often considered cost-competitive, price should not be the only factor when evaluating BOTULAX® for sale. Clinics that buy BOTULAX® wholesale typically compare cost per unit across vial sizes at their preferred dilution ratio rather than total order price alone. Selecting a reliable BOTULAX® supplier with proper cold-chain handling, regulatory compliance, and verified product authenticity is equally important when sourcing the product to help ensure consistent clinical use.

Clinical Benefits of BOTULAX®

BOTULAX® is a medical aesthetic product used in practice because it offers multiple vial sizes and competitive pricing. Hugel positions it as a leading botulinum toxin in CE-marked international markets, supported by approval from the Korean Ministry of Food and Drug Safety (MFDS) and CE marking, allowing distribution across many European and UK markets [3].

Practical advantages include:

• Cost-competitive pricing: Many aesthetic practices choose BOTULAX® as a more economical option compared to other botulinum toxin brands from Western manufacturers [5].
• Four vial sizes: Available in 50U, 100U, 200U, and 300U presentations, allowing practitioners to select the most appropriate size for different treatment protocols and patient volumes.
• Quality manufacturing: Produced under strict quality control and established South Korean manufacturing standards with rigorous oversight throughout production.
• International availability: CE marking supports broader access in international markets alongside domestic MFDS approval.

Many BOTULAX® reviews report consistent aesthetic results and good value for clinics. However, treatment outcomes depend on proper dosing, injection technique, patient selection, and adherence to recommended treatment protocols rather than the product alone [5].

Side Effects and Safety

Like all botulinum toxin type A products, BOTULAX® has an established safety profile when administered by trained healthcare professionals [1][5]. Most side effects are mild, temporary, and resolve without medical intervention.

Common side effects

• Bruising at the injection site
• Mild headache
• Localized swelling or tenderness

Treatment-specific side effects

• Temporary eyelid drooping (ptosis) following upper facial injections
• Dysphagia (difficulty swallowing) after neck treatments, including platysmal band correction

Rare but serious risks

• Spread of toxin effect beyond the injection site, which may cause muscle weakness in unintended areas. This is a recognized class-wide risk associated with all botulinum toxin type A products rather than being unique to BOTULAX® [5].

BOTULAX® is generally contraindicated in patients with:

• Neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome
• Pregnancy
• Known hypersensitivity to botulinum toxin or any component of the formulation

Following BOTULAX® post treatment precautions can help reduce the likelihood of unwanted toxin diffusion. Patients are typically advised to avoid rubbing the treated area, strenuous exercise, and excessive heat exposure for the recommended period after treatment. Practitioners who buy BOTULAX® products for clinical use should ensure that clear post-procedure instructions and appropriate patient education are part of every treatment protocol [1].

How to Find Information on Sourcing BOTULAX®

BOTULAX® is a prescription-only pharmaceutical, and legitimate access runs through authorized distributors supplying licensed medical professionals, not direct retail channels. Practitioners looking into where to buy BOTULAX® online should treat supplier verification as a clinical safety step, not paperwork:

• Confirm cold-chain compliance from manufacturer to point of delivery.
• Check LOT numbers against manufacturer records where possible.
• Request supplier credentials and distribution licensing documentation.
• Verify certificates of authenticity, particularly given the counterfeit risk that affects the botulinum toxin category broadly.

Anyone planning to order BOTULAX® wholesale should apply the same level of diligence used for any prescription pharmaceutical, as unverified or diverted products may compromise patient safety and treatment outcomes. The requirements to purchase BOTULAX® online vary by jurisdiction, and licensed professionals should verify what their regional regulations permit. Licensed healthcare professionals seeking additional information on product availability, product specifications, or supplier verification can contact Medical Spa Rx representatives for assistance.

Frequently Asked Questions

What is BOTULAX®?

BOTULAX® is a botulinum toxin type A injectable manufactured by Hugel Inc. in South Korea. Supplied as a lyophilized powder in 50U, 100U, 200U, and 300U vials, it holds regulatory approvals including CE marking for aesthetic and therapeutic use in a number of international markets.

Is BOTULAX® the same as BOTOX®?

No. They come from different manufacturers and are not interchangeable products. BOTULAX® contains letibotulinumtoxinA (Hugel); BOTOX® contains onabotulinumtoxinA (AbbVie). Units are not directly interchangeable between the two. “Botox” is often used colloquially to mean any toxin brand, but clinically these are distinct products.

What vial sizes does BOTULAX® come in?

50U for precision work and fine lines, 100U for standard aesthetic use, 200U for higher-volume treatment, and 300U for hyperhidrosis, large-area, or therapeutic use. The 100U vial is the most commonly used size in general aesthetic practice.

How is BOTULAX® reconstituted?

Typically, 2.5 to 5 mL of sterile 0.9% saline is added to the 100U vial, with gentle rotation rather than shaking. This gives roughly 4U per 0.1 mL at a 2.5 mL dilution, or 2U per 0.1 mL at a 5 mL dilution. Reconstituted product should be used within 24 hours and kept refrigerated, though some practitioners prefer use within 4 hours for optimal potency.

How long do BOTULAX® results last?

Onset is generally reported at 3 to 7 days, with full effect visible by 10 to 14 days. Duration is typically 3 to 4 months for aesthetic use, with some patients reporting effects up to 6 months, consistent with other letibotulinumtoxinA products in published clinical data [1].

Is BOTULAX® FDA-approved?

No. BOTULAX® holds regulatory approvals including CE marking across applicable international markets and is MFDS-approved in South Korea, but it does not hold FDA approval for the US market. Hugel’s FDA-approved product for the US is LETYBO®, a distinct formulation with its own INN.

Can BOTULAX® be combined with dermal fillers?

Yes, this is standard practice in comprehensive facial rejuvenation, since BOTULAX® addresses dynamic wrinkles while fillers address volume loss and static lines. Standard post-treatment precautions still apply, including avoiding rubbing, strenuous exercise for 24 hours, and remaining upright for around 4 hours.

Where can practitioners find information on sourcing BOTULAX®?

As a prescription-only pharmaceutical, BOTULAX® is available through authorized distributors to licensed medical professionals. Practitioners should verify supplier credentials, cold-chain compliance, and documentation including LOT numbers and certificates of authenticity before accepting stock.

This page and all of its contents are intended for medical professionals, designed to inform only, and are not a replacement for medical advice.

References

[1] Do KH, Chun MH, Paik NJ, et al. Safety and efficacy of letibotulinumtoxinA(BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial. Clin Rehabil. 2017;31(9):1179-1188. doi:10.1177/0269215516689331 

[2] U.S. Food and Drug Administration. Drug Trials Snapshots: LETYBO. FDA.gov. Published April 29, 2026. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-letybo

[3] Chen R. Botox by Another Name: Which Botulinum Toxins Are Approved by Country. Aesthetic Medical Guide. Published July 15, 2026. https://aestheticmedguide.com/blog/botulinum-toxin-brands-approved-by-country-botox-dysport-nabota-botulax

[4] Bravo M, Vogel K, Sternfels W, Touchet N, Turegano M. Botulax and the US development. Dermatological Reviews. 2022;3(4):231-235. doi:10.1002/der2.162

[5] Won CH, Lee HM, Lee WS, et al. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171-178. doi:10.1111/dsu.12072